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OPEN LETTER
Insights from quantitative and mathematical modelling on the
 proposed WHO 2030 goals for Chagas disease [version 1; peer
review: 2 approved]
Collaborating Group on Chagas Disease Modelling
Abstract
Chagas disease (CD) persists as one of the neglected tropical diseases
(NTDs) with a particularly large impact in the Americas. The World Health
Organization (WHO) recently proposed goals for CD elimination as a public
health problem to be reached by 2030 by means of achieving
intradomiciliary transmission interruption (IDTI), blood transfusion and
transplant transmission interruption, diagnostic and treatment scaling-up
and prevention and control of congenital transmission. The NTD Modelling
Consortium has developed mathematical models to study Trypanosoma
transmission dynamics and the potential impact of control measures.cruzi 
Modelling insights have shown that IDTI is feasible in areas with sustained
vector control programmes and no presence of native triatomine vector
populations. However, IDTI in areas with native vectors it is not feasible in a
sustainable manner. Combining vector control with trypanocidal treatment
can reduce the timeframes necessary to reach operational thresholds for
IDTI (<2% seroprevalence in children aged <5 years), but the most
informative age groups for serological monitoring are yet to be identified.
Measuring progress towards the 2030 goals will require availability of vector
surveillance and seroprevalence data at a fine scale, and a more active
surveillance system, as well as a better understanding of the risks of vector
re-colonization and disease resurgence after vector control cessation. Also,
achieving scaling-up in terms of access to treatment to the expected levels
(75%) will require a substantial increase in screening asymptomatic
populations, which is anticipated to become very costly as CD prevalence
decreases. Further modelling work includes refining and extending
mathematical models (including transmission dynamics and statistical
frameworks) to predict transmission at a sub-national scale, and developing
quantitative tools to inform IDTI certification, post-certification and
re-certification protocols. Potential perverse incentives associated with
operational thresholds are discussed. These modelling insights aim to
inform discussions on the goals and treatment guidelines for CD.
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Background
With an estimated 8–10 million cases worldwide, Chagas dis-
ease (CD; also known as American trypanosomiasis) remains a 
major cause of heart disease morbidity, mortality and economic 
burden, particularly in endemic Latin American countries1. CD is 
a parasitic disease caused by the protozoan Trypanosoma cruzi, 
and transmitted mainly by domiciliated triatomine (Reduvii-
dae) vectors (kissing bugs) in tropical areas of the Americas. 
However, along with the urbanization process in recent decades, 
other transmission routes, such as blood transfusion, organ trans-
plant and congenital have become important in both endemic and 
non-endemic countries2. The disease is characterized by a long 
asymptomatic period (years to decades) before reaching the full 
set of clinical manifestations that include heart failure, arryth-
mias, stroke, digestive complications and other conditions 
that increase the risk of death3.
From the beginning of the Southern Cone Initiative in the 1990s, 
most endemic countries have made great progress towards the 
control of T. cruzi transmission by implementing mainly vec-
tor control (chiefly through indoor residual-insecticide spray-
ing (IRS)) and blood transfusion control via donor screening. So 
far, 11 out of the 21 recognised endemic countries have been cer-
tified as having reached intradomiciliary transmission interrup-
tion (IDTI)4. However, the real impact of such interventions has 
not been rigorously documented and quantified, and various con-
cerns have been raised around the relationship between reaching 
the various operational thresholds that have been proposed and 
truly achieving interruption/elimination of transmission and 
reduction in morbidity5. Also, the increased health-care demands 
from the chronically-affected populations, and the limited offer 
of diagnosis and trypanocidal and supportive treatment pose 
additional challenges to CD control.
The World Health Organization (WHO) has set goals for the con-
trol of CD by 2030 in both endemic and non-endemic countries, 
including achieving the target of elimination as a public health 
problem (EPHP), the interruption of the various transmission 
routes and the scale-up of diagnosis and treatment strategies 
(a summary of these goals is presented in Table 1). In order to help 
evaluate progress towards and feasibility of these goals, math-
ematical modellers from different countries have joined forces, 
under the invitation of the Bill & Melinda Gates 
Foundation-funded NTD Modelling Consortium, to contribute 
to a joint analysis of mathematical modelling insights to support 
the CD WHO goals for 2030. In February 2018 a workshop on 
“How can modelling contribute to achieving the goals for Cha-
gas disease in the Horizon 2020 and beyond?” was held at Impe-
rial College London, with participants contributing ideas on how 
to quantitatively inform global progress on control and elimi-
nation of CD. In this document, we consolidate the main points 
from these discussions, involving ecological and epidemiologi-
cal modellers and researchers from Imperial College London and 
Sussex University UK, Princeton University and University 
of Pennsylvania USA, University of Perpignan Via Domitia 
France, University of La Plata and CONICET Argentina, and 
Fundação Oswaldo Cruz – Fiocruz, Brazil.
Insights gained from quantitative and mathematical 
modelling analyses
Intra-domiciliary transmission interruption (IDTI)
A main planned target is achieving IDTI in endemic countries 
with 0% colonization of dwellings and 0% incidence of T. cruzi-
infected persons (Table 1). The accumulated body of knowl-
edge from the modelling work that has been undertaken by these 
groups over the last years tends to agree on various aspects, par-
ticularly the important progress made towards IDTI. Reductions 
of incidence and disease burden through the control or elimina-
tion of introduced/non-native Triatoma infestans (in some areas 
of the Southern Cone such as Brazil, Uruguay, and pockets 
of Paraguay, Chile, Peru, and Argentina) and of Rhodnius pro-
lixus (in Central America and some pockets in Northern South 
America) have been achieved by a combination of IRS, locally 
practicable environmental management strategies and hous-
ing improvement, as initially suggested by pioneer mathematical 
modelling6. However, enormous challenges and limitations persist 
in terms of sustainability, data availability to monitor progress or 
re-emergence (which includes vector re-introduction (or resur-
gence from residual foci) and re-emergence of transmission), 
and clarity in the specific strategies to be undertaken towards 
the achievement of the 2030 goals.
IDTI is potentially achievable in epidemiological settings with 
exclusively domiciliary (i.e., non-native) vectors and no insec-
ticide resistance. Pioneer work also illustrated an application of 
triatomine-population modelling to optimize IRS for vector con-
trol, suggesting how to determine the optimal timing of spray-
ing for the control of T. infestans in Argentina, depending on the 
season and the structure of the triatomine population7. Using a 
similar approach with current techniques will be useful to help 
programmes to better target IRS strategies against domicili-
ated vectors. The critical (threshold) number of triatomines 
per house related to transmission risk, and how this can be used 
to prioritize vector control campaigns, has been investigated. 
A relationship between house infestation (proportion of houses 
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infested) and the number of triatomines/house was fitted to data 
from various locations prior to vector control and applied to 
cases where there was only one triatomine species present in 
the dwellings, as well as to situations with mixtures of species 
and developmental stages, various types of houses and bug den-
sities per house. These relationships can be improved when data 
are stratified (if available) with some critical co-variates, such as 
house-construction materials, number of humans and zoonotic 
hosts in the dwellings, and IRS status8,9. Understanding further 
these relationships taking into account other variables (such as 
the distribution of triatomines per house, the triatomine spe-
cies, the time elapsed after intervention, etc.), will be crucial to 
determine operational thresholds that lead to cost optimisation10.
However, large areas of endemic countries with domiciliated 
vector species have sylvatic populations (for which traditional 
vector control measures are less effective). An example is Rhod-
nius prolixus, a vector that has been targeted for elimination 
in Central and South America. Unlike Central America, where 
R. prolixus is strictly domiciliated11, large areas of Colombia
and Venezuela have R. prolixus as the most prominent sylvatic
species. In these areas re-colonisation occurs readily between
1 to 67 months after IRS12. In the presence of sylvatic popula-
tions, there is a continuous introduction and colonisation of
domiciliary and peri-domiciliary habitats; in these areas, traditional 
vector control is not feasible in a sustainable manner. Addition-
ally, even if the domiciliated vector species are eliminated, their 
niche could be taken over by other sylvatic vector species.
Various studies on routine vector surveillance have demonstrated 
that the currently used methods have low sensitivity and greatly 
underestimate vector density, infestation and infection rates; vec-
tor surveillance may be capturing half of infestations – and, 
most likely, most bugs within a house13,14. These shortcomings 
may have greater impact in low-prevalence and post-intervention 
settings.
Measuring 0% incidence requires analysis of seroprevalence 
studies, but diagnostic tests do not have perfect sensitivity and 
specificity. Investment in Research and Development (R&D) is 
essential to improve the performance of serology-based tests, 
particularly in near-elimination (low-prevalence) settings. Also, 
hierarchical models can be used to estimate test performance 
parameters (sensitivity and specificity) and then correct infec-
tion frequency14. The most informative age classes for sero-
monitoring should be identified, and strategies developed for 
monitoring the long-term response to control. Modelling the 
historical force-of-infection (FOI; the per susceptible incidence 
Table 1. Summary of modelling insights and challenges for reaching the WHO 2030 goals for Chagas disease (CD).
Current WHO Goal (2020) 1) Interruption of intradomiciliary (vectorial) transmission in the Americas 
2) Interruption of transfusional transmission by blood/blood products in the Americas, Europe and
Western Pacific
WHO new targets (2030) 1) Elimination as a public health problem (EPHP, 20 endemic countries + 75% access to treatment); 
2) Interruption of intradomiciliary (vectorial) transmission (IDTI) with 0% colonization of dwellings and
0% incidence of T. cruzi-infected persons; 3) Elimination of blood transfusion-related transmission
(BTT) in 100% of the target countries; 4) Elimination of tissue transplant-related transmission (TTT) (in
100% of the target countries; 5) Interruption of congenital transmission (CTI) of Chagas disease: 90%
screening coverage and treatment to women, and when infected, screening of their new-borns and
siblings.
Are the new targets technically 
feasible under the current 
intervention strategy?
Achieving IDTI in areas with coexistent transmission by native vectors is not feasible in a sustainable 
manner; BTT and TTT are potentially achievable but a clear protocol of strategies for achieving 
these goals is needed; 100% treatment of women of childbearing age is not feasible (a proportion of 
women have contraindications and abandonment of treatment has been estimated at 20%). 100% 
diagnosis in new-borns is not feasible (parasitological test sensitivity <30% and infrastructure for 
more sensitive tests (qPCR) is far from optimal).
If not, what is required to achieve 
the targets?
When current vector control strategy is combined with annual trypanocidal treatment in 10% of 
the infected human population, the seroprevalence (operational) criterion (<2% in under 5-year 
old children) could be achieved in 1/3 of the time (11 years in highly-endemic settings). In order to 
achieve high treatment coverage, various parameters interact (probability of screening, sensitivity 
of the test, proportion of people receiving and adhering to complete treatment course and drug 
efficacy). The lowest of all these is currently screening (access to diagnosis <1%).
Are current tools able to reliably 
measure the targets?
Force-of-Infection (FOI) models using age-stratified seroprevalence data are a promising tool to 
measure efficacy of IDTI. Tools are required to evaluate BTT, TTT and CTI. The “0% colonization” 
target can only be measured very imperfectly with current vector-surveillance tools.
What are the biggest unknowns? Prevalence of infection and house infestation in many areas; role of native vector species in 
transmission; resistance status of vector populations to currently available insecticides; disentangling 
the impact of chemical vector control from that of housing improvement; efficacy of trypanocidal 
treatment under various rates of abandonment.
What are the biggest risks? Slacking elimination efforts before reaching EPHP; spread of insecticide resistance; not being able to 
identify and treat congenital cases; treatment of children with false positive results.
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rate) using population representative seroprevalence studies, is 
a promising quantitative tool to measure trends in incidence and 
achievement of operational thresholds for transmission interrup-
tion as done in Peru and Colombia15,16 (e.g. <2% seroprevalence in 
under 5-year-olds) (Figure 1). However, even if IDTI were 
achieved, the likely presence of remaining vector popula-
tions, the protracted temporal scale of T. cruzi transmission 
(decades), and the long asymptomatic period of infection, can 
lead to many years passing before parasite re-emergence is 
noticed. FOI (catalytic) models are also a promising tool to 
estimate time to resurgence when a strategy has not been suf-
ficiently effective, as applied in La Joya, Peru15 and the Bolivian 
Chaco17.
Modelling studies have indicated that potentially combining 
highly effective vector control with trypanocidal treatment of 
humans residing in endemic areas would substantially reduce the 
time required to achieve operational serological thresholds for 
IDTI as well as infection incidence and prevalence18 (Figure 2). 
Understanding the implications of this combination of inter-
ventions for achieving elimination of transmission and EPHP 
needs further work.
Understanding the role of sylvatic vectors
Native triatomines maintain extensive enzootic T. cruzi 
transmission cycles from the United States of America to 
Patagonia, including vast areas where the three main domestic 
vectors of human CD (Triatoma infestans, T. dimidiata, and 
Rhodnius prolixus) occur in the wild, with the potential for 
invading, infesting, and re-infesting dwellings. Challenges remain 
concerning the role and magnitude of rural and urban transmis-
sion, which are harder to quantify. In vast areas of endemic coun-
tries, intradomicilary transmission is due to ‘sylvatic’ species 
that do not colonize domiciles but only make occasional vis-
its (also called ‘intrusive’ species)19. This has led to research-
ers to suggest an alternative classification of triatomines that 
captures their complexity but is still operationally relevant for 
surveillance20.
Recent studies have modelled the relative roles of some can-
didate variables on house invasion by sylvatic triatomines21. 
Modelling studies suggest that a better comprehension of vec-
torial transmission in rural and urban settings would require 
understanding and quantifying of two different forms of vector 
dispersal, namely, dispersal between sylvatic and non-sylvatic 
habitats and diffusive dispersal within cities22.
A promising avenue is the application of orthogonal polynomi-
als methods to predict triatomine dispersal based upon exclu-
sively life-history data of each triatomine species23. Tackling 
transmission by native vectors may necessitate alternative control 
strategies, which would require measuring dispersal and evalu-
ating the efficacy of strategies such as those used for other 
vector-borne diseases, e.g. (impregnated) nets. Examples of 
the application of transmission dynamics and statistical mod-
els to evaluate both dispersal and the potential efficacy of such 
alternative strategies in comparison to typical IRS have been 
discussed22.
Figure 1. Force-of-Infection (FOI) models fitted to seroprevalence data. Upper panels represent the (modelled) historical FOI. Lower 
panels present the data (solid squares) and the modelled seroprevalence (orange shaded area) in: (A) a non-intervened area with a long-
established endemic situation and (B) a successfully intervened area. This figure has been reproduced from 15 under a Creative Common 
Attribution 4.0 International Licence (CC BY 4.0).
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Scaling up screening and treatment strategies
Another main target planned is achieving 75% access to trypano-
cidal treatment in T. cruzi-infected people with medical indi-
cations (Table 1). Trypanocidal treatment with benznidazole 
(BNZ) or nifurtimox (NFX) has been aimed at both reducing 
parasitaemia and curbing disease progression. So far, there is 
limited evidence on the efficacy of drugs for these.
Monotherapy with BNZ has been proven to reduce parasitae-
mia in up to 86.7% of treated patients24. However, it is known 
that the trypanocidal effect of BNZ varies across regions25,26. The 
evidence of trypanocidal efficacy for NFX is more scarce than 
for BNZ; unlike BZN, there is only one completed trial with 
27 people treated and 24 placebo controls27. According to a 2014 
Cochrane systematic review, there is not robust evidence yet 
regarding efficacy on halting or delaying clinical progression28. 
Before the BENEFIT (BENznidazole Evaluation For Interrupting 
Trypanosomiasis) trial (a randomized trial of BNZ for chronic 
Chagas’ cardiomyopathy)26, observational studies had indi-
cated a possible impact on disease progression and mortality. 
However, the BENEFIT trial was not able to demonstrate such 
effect29. Criticisms about the design and very optimistic assump-
tions about the true effect of trypanocidal treatment have been 
raised about this trial. BENEFIT’s authors designed this trial 
assuming a high (26%) reduction relative to placebo in the 
incidence of cardiac complications among individuals with mod-
erate to advanced cardiac disease. The trial identified a small 
(7%), but apparently consistent reduction of such outcomes, 
which may still be relevant for patients and from a public health 
perspective. For that small, but still relevant effect size, its sam-
ple size may have been underestimated (low-quality evidence 
for imprecision and lack of consistency with other studies, fol-
lowing GRADE criteria)30. Using the current regimens of BNZ 
or NFX (60-day treatment course), only 70% of patients adhere 
to treatment on average, mostly due to adverse effects26. How-
ever, alternative regimes with shorter duration or lower doses 
have been trialled (e.g. BENDITA trial31) with promising results. 
This could lead to crucially improved adherence. Finally, an 
earlier diagnosis of cardiomyopathy and more comprehen-
sive (supportive) treatment for heart failure may reduce mortal-
ity and hospitalizations by 20–30% (assuming, and yet to be 
tested, that such treatment has an effect similar to other causes of 
cardiovascular disease).
Modelling work has shown that an optimal combination of 
parameters such as: coverage of screening; performance of diag-
nostic tests; proportion of people treated; and efficacy of trypano-
cidal drugs is crucial to the scale-up of diagnosis and treatment 
programmes. While screening and access to treatment can be 
incremented as part of strengthening health systems, improving 
Figure 2. Combined impact of vector control and effective parasite clearance. Annual vector control defines the proportion by which 
vector density is annually reduced (0–100%); parasite clearance is measured as proportion of parasitological cure (PPC); annual PPC defines 
the proportion of humans effectively treated annually with trypanocidal treatment, i.e., the percentage of the infected human population 
achieving parasitological cure (0–40%). The impact of the combined strategies is measured on the number of years necessary to reduce 
seroprevalence in children aged <5 years to <2% (the operational serological criterion for intradomiciliary transmission interruption), as 
represented by the colour scale. The panels represent: (A) low; (B) moderate; (C) high; and (D) very high endemicity levels. This figure has 
been reproduced from 17 under a Creative Common Attribution 4.0 International Licence (CC BY 4.0).
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diagnostics performance and drug efficacy will require con-
certed efforts18. With the current tools, low access to screening 
is the bottleneck; achieving just 10% of successful treatment at 
population level will require an enormous investment on improv-
ing access to screening, especially when targeting asymptomatic 
populations in low prevalence settings, which currently 
prevail in most endemic areas18 (Figure 3).
Practical implications of the new targets
Achieving IDTI will require enhanced detection methods for 
domiciliated triatomines in low-infestation and low-prevalence set-
tings. In order to monitor progress, improving the design of sero-
logical surveys for low-endemicity settings will be critical. FOI 
modelling suggests that increasing the age range for seromoni-
toring, instead of limiting it to under 5s or under 15s (e.g. using 
all-age classes), would be useful to understand temporal changes 
in T. cruzi incidence and the impact of interventions. Also, 
recent modelling studies have tested strategies to integrate data 
and models to guide interventions in Arequipa, Peru32, which 
can be used to improve cost-effectiveness. Models of triatom-
ine dispersal and colonization, with evidence-based parameteri-
sation, are also needed to both understand their dynamics and 
design and test alternative control strategies22.
Current estimates of access to diagnostics and treatment are 
at <1%33. Reaching 75% by 2030 does not seem feasible 
using the current passive surveillance system. This goal would 
only be feasible if an optimized screening/treatment strategy 
is purposely designed for the targeted countries. Scaling-up 
current strategies needs a substantial commitment by such coun-
tries, and resource availability will be an issue. Also, the availabil-
ity of current drugs is suboptimal, and there is a recurring need 
for supportive medical treatment of the CD sequelae.
In order to achieve 100% coverage of screening strategies 
implemented in blood banks and transplantation centres, a sur-
veillance and administrative system needs to be put in place. 
Specifically, this requires more inter-sectorial collaboration, 
the participation of insurance companies, private/public insti-
tutions, the implementation of clear protocols, and a substan-
tial commitment of health systems to ensure full documentation 
of the process. The WHO has a project in progress to develop 
an exhaustive database called the “World Information System 
for the Control of Chagas Disease” (WISCC), with an agree-
ment with the Computer Centre of the Polytechnic University of 
Barcelona (Spain), that may be functional to these needs. Addi-
tionally, modelling could inform how widely screening should 
be done in non-endemic countries.
Achieving most of the goals currently stated for women and 
newborns seems challenging with the currently available tools 
(Table 1). Given the long asymptomatic period and the current 
Figure 3. Probability of achieving effective parasite clearance. (A) 10% proportion of parasitological cure (PPC); and (B) 20% of PPC 
in a Trypanosoma cruzi–infected human population based on the combined probability of being diagnosed and treated (with trypanocidal 
medication) for Chagas disease. The horizontal axis represents the combined contribution of diagnosis as a product of the proportion of 
infected people who are tested (pT) and the proportion of those tested with a positive test result, that is, the sensitivity of the test (pP). The 
vertical axis represents the combined contribution of treatment, as the product of the proportion of those testing positives who are treated 
with currently available trypanocidal drugs (pD) and respond to treatment by clearing parasites according to efficacy (pE). Coloured lines 
represent the proportion (p) of infected people who would have to be reached by a test-and-treat programme (90% [blue], 50% [red], 33% 
[green], and 20% [orange]) to achieve the desired level of effective PPC. This figure has been reproduced from 17 under a Creative Common 
Attribution 4.0 International Licence (CC BY 4.0).
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passive surveillance system for identifying cases of CD in 
endemic and non-endemic countries, it seems unfeasible that 90% 
of women of childbearing age will be screened. However, reach-
ing almost 100% of pregnant women is potentially feasible 
with the recent strategy EMTCT plus (elimination of mother-
to-child transmission of HIV, syphilis, Chagas, and perinatal 
hepatitis B), which adds mandatory surveillance tests during 
pregnancy for CD, planned to be in place in Colombia, Chile 
and Uruguay as pilot countries over the next few years34. How-
ever, it is currently unrealistic to achieve 100% of treatment in 
newborns infected, as the sensitivity of micro-haematocrit meth-
ods (with repeated test) has been estimated at 34.2%35. Repeated 
PCR-based tests can improve sensitivity up to 84.2%, but these 
tests are neither standardised nor widely available in endemic 
settings35. Controlling congenital Chagas transmission would 
require urgent research for new diagnostics and drugs/drug 
regimes. Increased medical training and availability of tests and 
drugs would also need to be markedly improved. Higher sensitiv-
ity to detect congenital cases could also be achieved by including 
not only newborns, but also infants, for whom serological testing 
can be used from 8 months of age36. Finally, careful planning and 
organization would also be essential for reaching and covering 
the more inaccessible rural (and indigenous) populations, which 
are likely to contribute disproportionately to the burden of CD.
Risks and perverse incentives
Certifying intradomiciliary transmission interruption (IDTI) 
when such transmission has not truly been eliminated is the big-
gest risk. Current diagnostic tools are unlikely to be able to deter-
mine when true elimination has been achieved. However, it is 
perceived by public health officials that not having some reward 
system may harm even further the willingness of the countries 
towards elimination efforts. As countries reach low incidence, 
they may feel that efforts can be slackened. Determining the risk 
of re-colonisation after vector control is stopped and not having 
the tools to identify resurgence in a timely manner will, there-
fore, be important challenges. Developing and validating tools 
to quantify these risks will, in turn, inform ongoing initiatives 
to refine the process of re-certification that would follow after 
a (so far unspecified) number of years of the initial certification.
In terms of scaling-up treatment, it is anticipated that rare adverse 
effects of currently available drugs will become more evident. 
Also, in low-endemicity settings, the absolute number of false 
positives will be substantial as the number of people tested 
increase, even if specificity is high (98%, as estimated in a recent 
meta-analysis)37. Similarly, treating false-positive cases can 
become a particularly important issue, as the absolute number of 
such cases will increase when diagnosis implementation and access 
increases.
Moving towards elimination of transmission
Currently, endemic and non-endemic countries have been work-
ing on their own according to their priorities and resources, but 
a transition to realistic elimination goals at a global scale will 
require the concourse of both governmental and non-governmental 
organizations.
IDTI is only feasible in a few areas of exclusively domiciliated, 
non-native vectors. Once IDTI is achieved in a region, and the 
control programme is stopped, surveillance will be needed to 
detect resurgence. Currently, this occurs only over a few years 
after initial certification, but there is little knowledge and 
guidance available for this post-certification surveillance.
Large areas in endemic countries are populated by sylvatic tri-
atomine species for which traditional vector control is not effec-
tive in a sustainable manner. For those areas more experimental 
and modelling work is needed to better understand both 
transmission and control strategies.
Scaling-up diagnosis and treatment strategies will require not 
only a greater commitment of the health systems but also an 
important investment in terms of R&D for diagnostics and 
treatment strategies.
Modelling priorities to support goals in the 2030 
horizon and beyond
Table 2 outlines the priority modelling questions for fur-
ther research that were elaborated in discussion with 
the WHO.
Table 2. Summary of priority questions that can be answered with mathematical modelling.
Priority issue/question identified in discussions 
with WHO and PAHO
How can quantitative and mathematical modelling address this?
1. Monitoring progress towards 2030 goals Generate projections of both transmission and disease burden at sub-national 
level.
2. Assess potential for resurgence when vector control
interventions are stopped
Anticipate the risk and intensity of resurgence in different epidemiological 
scenarios and with different vector species.
3. Assess alternative control strategies for sylvatic
vectors transmitting in both urban and rural areas
Understand sylvatic transmission cycles in both rural and urban areas and test 
alternative control strategies.
4. Evaluate the impact of scaling up diagnosis and
treatment strategies
Predict the epidemiological impact of different strategies. 
Conduct cost-effectiveness analyses.
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Data (and software) availability
No data are associated with this article.
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